Effectiveness and safety of monoclonal antibodies for metastatic colorectal cancer treatment: Systematic review and meta-analysis

ecancermedicalscience

Volumn 9, Issue , 2015, Pages

  Rosa, Bruno ^a   De Jesus, Jose Paulo ^a   De Mello, Eduardo L ^a   Cesar, Daniel ^a   Correia, Mauro M ^a  

^a INSTITUTO NACIONAL DE CÂNCER   (Brazil)

Author keywords

Bevacizumab; Cetuximab; Colorectal neoplasia; Etastatic colorectal cancer; Monoclonal antibody; Panitumumab

Indexed keywords

BEVACIZUMAB; CAPECITABINE PLUS OXALIPLATIN; CEDIRANIB; CETUXIMAB; FLUOROPYRIMIDINE; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; OXALIPLATIN; PANITUMUMAB; PLACEBO;

ARTICLE; CANCER GROWTH; CANCER IMMUNOTHERAPY; CANCER SURGERY; COLORECTAL SURGERY; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; HUMAN; META ANALYSIS; METASTATIC COLORECTAL CANCER; ONCOGENE K RAS; OUTCOME ASSESSMENT; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); SYSTEMATIC REVIEW;

EID: 84960401367     PISSN: None     EISSN: 17546605     Source Type: Journal    
DOI: 10.3332/ecancer.2015.582     Document Type: Article

References (120)

1. Cancer Facts and Figures (2011) American Cancer Society Atlanta
2. Van Roosbroeck S, Hoeck S and Van Hal G (2012) Population-based screening for colorectal cancer using an immunochemical fecal occult blood test: A comparison of two invitation strategies Cancer Epidemiol 36(5) 317-24 DOI: 10.1016/j. canep.2012.04.003
3. Elias E et al (2012) Lymph node ratio is an independent prognostic factor in Stage III colorectal cancer patients: a retrospective study from the Middle East World J Surg Oncol 10 63-70 DOI: 10.1186/1477-7819-10-63
4. Deschoolmeester V et al (2010) A review of the most promising biomarkers in colorectal cancer: one step closer to targeted therapy Oncologist 15(7) 699-731 DOI: 10.1634/theoncologist.2010-0025 PMID: 20584808 PMCID: 3228001
5. Figueras J et al (2013) Preoperative treatment with bevacizumab in combination with chemotherapy in patients with unresectable metastatic colorectal carcinoma Clin Transl Oncol 15(6) 460-6 DOI: 10.1007/s12094-012-0952-6
6. Papa A et al (2012) Emerging role of cetuximab in the treatment of colorectal cancer Recent Pat Anticancer Drug Discov 7(2) 233-47 DOI: 10.2174/157489212799972882 PMID: 22264223
7. Satram-Hoang S et al (2013) Comparative Effectiveness of Chemotherapy in Elderly Patients with Metastatic Colorectal Cancer J Gastrointest Cancer 44(1) 79-88 DOI: 10.1007/s12029-012-9450-x PMCID: 3568483
8. Incidência de câncer no Brazil (2013) Instituto Nacional de Câncer José Alencar Gomes da Silva, Coordenação Geral de Ações Estratégicas Coordenação de Prevenção e Vigilância-Rio de Janeiro Brazil
9. Michor F et al (2005) Dynamics of colorectal cancer Semin Cancer Biol 15(6) 484-93 DOI: 10.1016/j.semcancer.2005.06.005 PMID: 16055342
10. Tol J and Punt CJ (2010) Monoclonal antibodies in the treatment of metastatic colorectal cancer: a review Clinical Therapeutics 32(3) 437-53 DOI: 10.1016/j.clinthera.2010.03.012 PMID: 20399983
11. Wang L, Chen X, Li W and Sheng Z (2012) Antiepidermal growth factor receptor monoclonal antibody improves survival outcomes in the treatment of patients with metastatic colorectal cancer Anti-Cancer Drugs 23(2) 155-60 DOI: 10.1097/CAD.0b013e32834c3256
12. Benoist S and Nordlinger B (2009) The role of preoperative chemotherapy in patients with resectable colorectal liver metastases Ann Surg Oncol 2009 16(9) 2385-90 DOI: 10.1245/s10434-009-0492-7 PMID: 19554377
13. Herbertson RA et al (2012) Epidermal growth factor receptor (EGF-R) inhibitors for metastatic colorectal cancer (Protocol for a Cochrane Review) The Cochrane Library Issue 11
14. Peeters M et al (2012) Panitumumab in Combination With Cytotoxic Chemotherapy for the Treatment of Metastatic Colorectal Carcinoma Clinical Colorectal Cancer 11(1) 14-23 DOI: 10.1016/j.clcc.2011.06.010
15. Wagner Anna DADW et al (2012) Anti-angiogenic therapies for metastatic colorectal cancer. Cochrane Database of Systematic Reviews in The Cochrane Library Issue 12
16. Douillard JY, Bennouna J and Senellart H (2008) Is XELOX equivalent to FOLFOX or other continuous-infusion 5-fluorouracil chemotherapy in metastatic colorectal cancer? Clin Color Cancer 7(3) 206-11 DOI: 10.3816/CCC.2008.n.029
17. Nordlinger B et al (2008) Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial Lancet 371(9617) 1007-16 DOI: 10.1016/S0140-6736(08)60455-9 PMID: 18358928 PMCID: 2277487
18. Boostrom SY et al (2009) Impact of neoadjuvant chemotherapy with FOLFOX/FOLFIRI on disease-free and overall survival of patients with colorectal metastases J Gastrointest Surg 13(11) 2003-9 DOI: 10.1007/s11605-009-1007-3 PMID: 19760306 PMCID: 2813967
19. Chibaudel B et al (2012) Therapeutic strategy in unresectable metastatic colorectal cancer Ther Adv Med Oncol 4(2) 75-89 DOI: 10.1177/1758834011431592 PMID: 22423266 PMCID: 3296081
20. Huang MY et al (2011) Prospective analysis of KRAS wild-type patients with metastatic colorectal cancer using cetuximab plus FOLFIRI or FOLFOX4 treatment regimens Genet Mol Res 10(4) 3002-12 DOI: 10.4238/2011.October.3.4 PMID: 21968808
21. Stintzing S et al (2009) The treatment of colorectal carcinoma with monoclonal antibodies. The importance of KRAS mutation analysis and EGFR status Dtsch Arztebl Int 106(12) 202-6 PMID: 19471640 PMCID: 2680580
22. Broadbridge VT, Karapetis CS and Price TJ (2012) Cetuximab in metastatic colorectal cancer Expert Rev Anticancer Ther 12(5) 555-65 DOI: 10.1586/era.12.25 PMID: 22594891
23. Cunningham D et al (2004) Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer N Engl J Med 351(4) 337-45 DOI: 10.1056/NEJMoa033025 PMID: 15269313
24. García-Foncillas J and Díaz-Rubio E (2010) Progress in metastatic colorectal cancer: growing role of cetuximab to optimize clinical outcome Clin Transl Oncol 12(8) 533-42 DOI: 10.1007/s12094-010-0551-3 PMID: 20709651
25. Brink M et al (2003) K-ras oncogene mutations in sporadic colorectal cancer in The Netherlands Cohort Study Carcinogenesis 24(4) 703-10 DOI: 10.1093/carcin/bgg009 PMID: 12727799
26. Kressner U et al (1998) Ki-ras mutations and prognosis in colorectal cancer Eur J Cancer 34(4) 518-21 DOI: 10.1016/S0959-8049(97)10111-3 PMID: 9713302
27. Bos JL (1990) Ras oncogenes in human cancer: a review Cancer Res 49(17) 4682-9
28. Fearon ER and Vogelstein B (1990) A genetic model for colorectal tumorigenesis Cell 61(5) 759-67 DOI: 10.1016/0092-8674(90)90186-I PMID: 2188735
29. Jonker DJ et al (2007) Cetuximab for the treatment of colorectal cancer. N Engl J Med 357(20) 2040-8 DOI: 10.1056/NEJMoa071834 PMID: 18003960
30. Keating GM (2010) Panitumumab: a review of its use in metastatic colorectal cancer Drugs 70(8) 1059-78 DOI: 10.2165/11205090-000000000-00000 PMID: 20481659
31. Giusti RM et al (2008) US Food and Drug Administration approval: panitumumab for epidermal growth factor receptor expressing metastatic colorectal carcinoma with progression following fluoropyrimidine, oxaliplatin, and irinotecan-containing chemotherapy regimens Clin Cancer Res 14(5) 1296-302 DOI: 10.1158/1078-0432.CCR-07-1354 PMID: 18316547
32. Tappenden P et al (2007) Systematic review and economic evaluation of bevacizumab and cetuximab for the treatment of metastatic colorectal cancer Health Technol Assess 11(12) 1-128 DOI: 10.3310/hta11120 PMID: 17346499
33. Bennouna J et al (2013) Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomized phase 3 trial Lancet Oncol 14(1) 29-37 DOI: 10.1016/S1470-2045(12)70477-1
34. Masi G et al (2010) Bevacizumab with FOLFOXIRI (irinotecan, oxaliplatin, fluorouracil, and folinate) as first-line treatment for metastatic colorectal cancer: a phase 2 trial Lancet Oncol 11(6) 845-52 DOI: 10.1016/S1470-2045(10)70175-3 PMID: 20702138
35. Bidard FC et al (2010) Single circulating tumor cell detection and overall survival in nonmetastatic breast cancer Ann Oncol 21(4) 729-33 DOI: 10.1093/annonc/mdp391
36. Saad ED and Katz A (2009) Progression-free survival and time to progression as primary end points in advanced breast cancer: often used, sometimes loosely defined Ann Oncol 20(3) 460-4 DOI: 10.1093/annonc/mdn670
37. Eisenhauer EA et al (2009) New response evaluation criteria in solid tumours: revised RECIST guideline (version1.1) Eur J Cancer 45(2) 228-47 DOI: 10.1016/j.ejca.2008.10.026
38. metaRegister of Controlled Trials (mRCT) [www.controlled-trials.com/mrct/] date accessed: 3 March 2014
39. Hurwitz H et al (2004) Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer N Engl J Med 350(23) 2335-42 DOI: 10.1056/NEJMoa032691 PMID: 15175435
40. Kabbinavar F et al (2005) Addition of bevacizumab to bolus fluorouracil and leucovorin in first-line metastatic colorectal cancer: results of a randomized Phase II trial J Clin Oncol 23(16) 3697-705 DOI: 10.1200/JCO.2005.05.112 PMID: 15738537
41. Saltz LB et al (2008) Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study J Clin Oncol 26(12) 2013-9 DOI: 10.1200/JCO.2007.14.9930 PMID: 18421054
42. Peeters M et al (2010) Randomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer J Clin Oncol 28(31) 4706-13 DOI: 10.1200/JCO.2009.27.6055 PMID: 20921462
43. Douillard JY et al (2010) Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study J Clin Oncol 28(31) 4697-705 DOI: 10.1200/JCO.2009.27.4860 PMID: 20921465
44. Maughan TS et al (2011) Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial Lancet 377(9783) 2103-14 DOI: 10.1016/S0140-6736(11)60613-2 PMID: 21641636 PMCID: 3159415
45. Van Cutsem E et al (2009) Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer N Engl J Med 360(14) 1408-17 DOI: 10.1056/NEJMoa0805019 PMID: 19339720
46. Adams RA et al (2009) Toxicity associated with combination oxaliplatin plus fluoropyrimidine with or without cetuximab in the MRC COIN trial experience Br J Cancer 100(2) 251-8 DOI: 10.1038/sj.bjc.6604877 PMID: 19165196 PMCID: 2634710
47. Bokemeyer C et al (2009) Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer J Clin Oncol 27(5) 663-71 DOI: 10.1200/JCO.2008.20.8397
48. Sobrero AF et al (2008) EPIC: phase III trial of cetuximab plus irinotecan after fluoropyrimidine and oxaliplatin failure in patients with metastatic colorectal cancer J Clin Oncol 26(14) 2311-9 DOI: 10.1200/JCO.2007.13.1193 PMID: 18390971
49. Borner M et al (2008) Adding cetuximab to capecitabine plus oxaliplatin (XELOX) in first-line treatment of metastatic colorectal cancer: a randomized phase II trial of the Swiss Group for Clinical Cancer Research SAKK Ann Oncol 19(7) 1288-92 DOI: 10.1093/annonc/mdn058 PMID: 18349029
50. Cui F et al (2009) Clinical research of bevacizumab in combination with irinotecan, fluorouracil and leucovorin for advanced metastatic colorectal cancer Zhonghua Wei Chang Wai Ke Za Zhi 12 374-7 PMID: 19598023
51. Stathopoulos GP et al (2010) Treatment of colorectal cancer with and without bevacizumab: a phase III study Oncology 78(5-6) 376-81 DOI: 10.1159/000320520 PMID: 20798560
52. Schmoll HJ et al (2012) Cediranib with mFOLFOX6 versus bevacizumab with mFOLFOX6 as first-line treatment for patients with advanced colorectal cancer: a double-blind, randomized phase III study (HORIZON III) J Clin Oncol 30(29) 3588-95 DOI: 10.1200/JCO.2012.42.5355 PMID: 22965961
53. Badarinath S et al (2004) Cetuximab plus FOLFOX for colorectal cancer (EXPLORE): Preliminary safety analysis of a randomized phase III trial J Clin Oncol 22 3531-9
54. Ye LC et al (2013) Randomized Controlled Trial of Cetuximab Plus Chemother-apy for Patients With KRAS Wild-Type Unresectable Colorectal Liver-Limited Metastases J Clin Oncol 31(16) 1931-8 DOI: 10.1200/JCO.2012.44.8308 PMID: 23569301
55. Colucci G et al (2010) Cetuximab plus FOLFOX-4 in untreated patients with advanced colorectal cancer: a Gruppo Oncologico dell'Italia Meridionale Multicenter phase II study Oncology 79(5-6) 415-22 DOI: 10.1159/000323279
56. Wong NS et al (2011) A phase II study of capecitabine, oxaliplatin, bevacizumab and cetuximab in the treatment of metastatic colorectal cancer Anticancer Res 31(1) 255-61 PMID: 21273607 PMCID: 4106457
57. Spigel DR et al (2010) Phase II trial of FOLFOX6, bevacizumab, and cetuximab in the first-line treatment of metastatic colorectal cancer Clin Adv Hematol Oncol 8(7) 480-5 498 PMID: 20864916
58. Boccia RV et al (2010) A phase II trial of FOLFOX6 and cetuximab in the first-line treatment of patients with metastatic colorectal cancer Clin Colorectal Cancer 9(2) 102-7 DOI: 10.3816/CCC.2010.n.014 PMID: 20378504
59. Raoul JL et al (2009) Cetuximab in combination with irinotecan/5-fluorouracil/folinic acid (FOLFIRI) in the initial treatment of metastatic colorectal cancer: a multicentre two-part phase I/II study BMC Cancer 9 112 DOI: 10.1186/1471-2407-9-112 PMID: 19366444 PMCID: 2678147
60. Tabernero J et al (2007) Phase II trial of cetuximab in combination with fluorouracil, leucovorin, and oxaliplatin in the first-line treatment of metastatic colorectal cancer J Clin Oncol 25(33) 5225-32 DOI: 10.1200/JCO.2007.13.2183 PMID: 18024868
61. Masi G et al (2010) Bevacizumab with FOLFOXIRI (irinotecan, oxaliplatin, fluorouracil, and folinate) as first-line treatment for metastatic colorectal cancer: a phase 2 trial Lancet Oncol 11(6) 845-52 DOI: 10.1016/S1470-2045(10)70175-3 PMID: 20702138
62. Lenz HJ et al (2004) Activity of cetuximab in patients with colorectal cancer refractory to both irinotecan and oxaliplatin J Clin Oncol 22 3510-14
63. Assenat E et al (2011) Cetuximab plus FOLFIRINOX (ERBIRINOX) as first-line treatment for unresectable metastatic colorectal cancer: a phase II trial Oncologist 16(11)1557-64 DOI: 10.1634/theoncologist.2011-0141 PMID: 22016477 PMCID: 3233290
64. Uehara K et al (2011) Conversion chemotherapy using cetuximab plus FOLFIRI followed by bevacizumab plus mFOLFOX6 in patients with unresectable liver metastases from colorectal cancer Jpn J Clin Oncol 41(10) 1229-32 DOI: 10.1093/jjco/hyr115 PMID: 21840871
65. Carneiro BA et al (2012) Phase II study of irinotecan and cetuximab given every 2 weeks as second-line therapy for advanced colorectal cancer Clin Colorectal Cancer 11(1) 53-9 DOI: 10.1016/j.clcc.2011.05.003
66. Kang MJ et al (2012) Biweekly cetuximab plus irinotecan as second-line chemotherapy for patients with irinotecan-refractory and KRAS wild-type metastatic colorectal cancer according to epidermal growth factor receptor expression status Invest New Drugs 30(4) 1607-13 DOI: 10.1007/s10637-011-9703-8
67. Ibrahim EM et al (2007) Safety and efficacy of cetuximab-chemotherapy combination in Saudi patients with metastatic colorectal cancer Indian J Cancer 44(2) 256-61 DOI: 10.4103/0019-509X.35812
68. Sobrero A et al (2009) Phase IV study of bevacizumab in combination with infusional fluorouracil, leucovorin and irinotecan (FOLFIRI) in first-line metastatic colorectal cancer Oncology 77(2) 113-9 DOI: 10.1159/000229787 PMID: 19628950
69. Van Cutsem E et al (2008) An open-label, single-arm study assessing safety and efficacy of panitumumab in patients with metastatic colorectal cancer refractory to standard chemotherapy Ann Oncol 19(1) 92-8 DOI: 10.1093/annonc/mdm399
70. Meyerhardt JA et al (2007) Phase II study of FOLFOX, bevacizumab and erlotinib as first-line therapy for patients with metastatic colorectal cancer Ann Oncol 18(7) 1185-9 DOI: 10.1093/annonc/mdm124 PMID: 17483115
71. Martín-Martorell P et al (2008) Biweekly cetuximab and irinotecan in advanced colorectal cancer patients progressing after at least one previous line of chemotherapy: results of a phase II single institution trial Br J Cancer 99(3) 455-8 DOI: 10.1038/sj.bjc.6604530 PMID: 18665167 PMCID: 2527794
72. Bennouna J et al (2012) Bevacizumab combined with chemotherapy in the second-line treatment of metastatic colorectal cancer: results from the phase II BEVACOLOR study Clin Colorectal Cancer 11(1) 38-44 DOI: 10.1016/j.clcc.2011.05.002
73. Saltz LB et al (2004) Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor J Clin Oncol 22(7) 1201-8 DOI: 10.1200/JCO.2004.10.182 PMID: 14993230
74. Galal KM, Khaled Z and Mourad AM (2011) Role of cetuximab and sorafenib in treatment of metastatic colorectal cancer Indian J Cancer 48(1) 47-54 DOI: 10.4103/0019-509X.75825 PMID: 21248446
75. Cunningham D et al (2004) Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer N Engl J Med 351(4) 337-45 DOI: 10.1056/NEJMoa033025 PMID: 15269313
76. Van Cutsem E et al (2012) Intrapatient cetuximab dose escalation in metastatic colorectal cancer according to the grade of early skin reactions: the randomized EVEREST study J Clin Oncol 30(23) 2861-8 DOI: 10.1200/JCO.2011.40.9243 PMID: 22753904
77. Moosmann N et al (2011) Cetuximab plus capecitabine and irinotecan compared with cetuximab plus capecitabine and oxaliplatin as first-line treatment for patients with metastatic colorectal cancer: AIO KRK-0104-A randomized trial of the German AIO CRC study group J Clin Oncol 29(8) 1050-8 DOI: 10.1200/JCO.2010.31.1936 PMID: 21300933
78. Tol J et al (2009) Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer N Engl J Med 360(6) 563-72 DOI: 10.1056/NEJMoa0808268 PMID: 19196673
79. Tol J et al (2008) A randomised phase III study on capecitabine, oxaliplatin and bevacizumab with or without cetuximab in first-line advanced colorectal cancer, the CAIRO2 study of the Dutch Colorectal Cancer Group (DCCG). An interim analysis of toxicity Ann Oncol 19(4) 734-8 DOI: 10.1093/annonc/mdm607 PMID: 18272912
80. Saltz LB et al (2007) Randomized phase II trial of cetuximab, bevacizumab, and irinotecan compared with cetuximab and bevacizumab alone in irinotecan-refractory colorectal cancer: the BOND-2 study J Clin Oncol 25(29) 4557-61 DOI: 10.1200/JCO.2007.12.0949 PMID: 17876013
81. Hecht JR et al (2009) A randomized phase IIIB trial of chemotherapy, bevacizumab, and panitumumab compared with chemotherapy and bevacizumab alone for metastatic colorectal cancer J Clin Oncol 27(5) 672-80 DOI: 10.1200/JCO.2008.19.8135
82. Lacouture ME et al (2010) Skin toxicity evaluation protocol with panitumumab (STEPP), a phase II, open-label, randomized trial evaluating the impact of a pre-emptive skin treatment regimen on skin toxicities and quality of life in patients with metastatic colorectal cancer J Clin Oncol 28(8) 1351-7 DOI: 10.1200/JCO.2008.21.7828 PMID: 20142600
83. Giessen C et al (2010) A randomized, phase III trial of capecitabine plus bevacizumab (Cape-Bev) versus capecitabine plus irinotecan plus bevacizumab (CAPIRI-Bev) in first-line treatment of metastatic colorectal cancer: the AIO KRK 0110 trial/ML22011 trial BMC Cancer 11 367-78 DOI: 10.1186/1471-2407-11-367
84. Tebbutt NC et al (2010) Capecitabine, bevacizumab, and mitomycin in first-line treatment of metastatic colorectal cancer: results of the Australasian Gastrointestinal Trials Group Randomized Phase III MAX Study J Clin Oncol 28(19) 3191-8 DOI: 10.1200/JCO.2009.27.7723 PMID: 20516443
85. Saltz L et al (2012) Phase III trial of cetuximab, bevacizumab, and 5-fluorouracil/leucovorin vs. FOLFOX-bevacizumab in colorectal cancer Clin Colorectal Cancer 11(2) 101-11 DOI: 10.1016/j.clcc.2011.05.006
86. Stintzing S et al (2012) FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer-subgroup analysis of patients with KRAS: mutated tumours in the randomised German AIO study KRK-0306 Ann Oncol 23(7) 1693-9 DOI: 10.1093/annonc/mdr571 PMID: 22219013
87. Zhi J et al (2011) A multicenter, randomized, open-label study to assess the steady-state pharmacokinetics of bevacizumab given with either XELOX or FOLFOX-4 in patients with metastatic colorectal cancer Cancer Chemother Pharmacol 68(5) 1199-206 DOI: 10.1007/s00280-011-1606-z PMID: 21409383
88. Azvolinsky A (2011) Oral anti-angiogenesis treatment plus chemotherapy is not more efficacious than bevacizumab plus chemotherapy in metastatic colorectal cancer Oncology 25(12) 1232-5
89. Tsutsumi S et al Phase II trial of chemotherapy plus bevacizumab as second-line therapy for patients with metastatic colorectal cancer that progressed on bevacizumab with chemotherapy: the Gunma Clinical Oncology Group (GCOG) trial 001 SILK study Oncology 83(3) 151-7 PMID: 22889925
90. Díaz-Rubio E et al (2012) First-line XELOX plus bevacizumab followed by XELOX plus bevacizumab or single-agent bevacizumab as maintenance therapy in patients with metastatic colorectal cancer: the phase III MACRO TTD study Oncologist 17(1) 15-25 DOI: 10.1634/theoncologist.2011-0249
91. Wolff RA et al (2012) A double-blind, randomized, placebo-controlled, phase 2 study of maintenance enzastaurin with 5-fluorouracil/leucovorin plus bevacizumab after first-line therapy for metastatic colorectal cancer Cancer 118(17) 4132-8 DOI: 10.1002/cncr.26692 PMID: 22213153
92. Kato S et al (2012) Safety verification trials of mFOLFIRI and sequential IRIS + bevacizumab as first-or second-line therapies for metastatic colorectal cancer in Japanese patients Oncology 83(2) 101-7 DOI: 10.1159/000339541 PMID: 22777333
93. Mitchell EP et al (2011) The efficacy and safety of panitumumab administered concomitantly with FOLFIRI or Irinotecan in second-line therapy for metastatic colorectal cancer: the secondary analysis from STEPP (Skin Toxicity Evaluation Protocol With Panitumumab) by KRAS status Clin Colorectal Cancer 10(4) 333-9 DOI: 10.1016/j.clcc.2011.06.004 PMID: 22000810
94. Pectasides D et al (2012) XELIRI-bevacizumab versus FOLFIRI-bevacizumab as first-line treatment in patients with metastatic colorectal cancer: a Hellenic Cooperative Oncology Group phase III trial with collateral biomarker analysis BMC Cancer 12 271-81 DOI: 10.1186/1471-2407-12-271 PMID: 22748098 PMCID: 3466131
95. Giantonio BJ et al (2007) Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200 J Clin Oncol 25(12) 1539-44 DOI: 10.1200/JCO.2006.09.6305 PMID: 17442997
96. Kabbinavar F et al (2003) Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer J Clin Oncol 21(1) 60-5 DOI: 10.1200/JCO.2003.10.066
97. Hurwitz H et al (2003) Bevacizumab (a monoclonal antibody to vascular endothelial growth factor) prolongs survival in firstline colorectal cancer (CRC): results of a phase III trial of bevacizumab in combination with bolus IFL (irinotecan, 5-fluorouracil, leucovorin) as first-line therapy in subjects with metastatic CRC Proc Am Soc Clin Oncol 22 906
98. Folprecht G et al (2010) Tumour response and secondary resectability of colorectal liver metastases following neoadjuvant chemotherapy with cetuximab: the CELIM randomised phase 2 trial Lancet Oncol 11(1) 38-47 DOI: 10.1016/S1470-2045(09)70330-4
99. Hurwitz HI et al (2005) Bevacizumab in combination with fluorouracil and leucovorin: an active regimen for first-line metastatic colorectal cancer J Clin Oncol 23(15) 3502-8 DOI: 10.1200/JCO.2005.10.017 PMID: 15908660
100. Reidy DL et al (2010) Randomized, phase II study of the insulin-like growth factor-1 receptor inhibitor IMC-A12, with or without cetuximab, in patients with cetuximab or panitumumab refractory metastatic colorectal cancer J Clin Oncol 28 4240-6 DOI: 10.1200/JCO.2010.30.4154 PMID: 20713879 PMCID: 3296668
101. Tveit KM et al (2012) Phase III trial of cetuximab with continuous or intermittent fluorouracil, leucovorin, and oxaliplatin (Nordic FLOX) versus FLOX alone in first-line treatment of metastatic colorectal cancer: the NORDIC-VII study J Clin Oncol 30(15) 1755-62 DOI: 10.1200/JCO.2011.38.0915 PMID: 22473155
102. Venook A et al (2006) Phase III study of irinotecan/5FU/LV (FOLFIRI) or oxaliplatin/5FU/LV (FOLFOX) ± cetuximab for patients (pts) with untreated metastatic adenocarcinoma of the colon or rectum (MCRC): CALGB 80203 preliminary results J Clin Oncol 24 3509
103. Hochster HS et al (2008) Safety and efficacy of oxaliplatin and fluoropyrimidine regimens with or without bevacizumab as first-line treatment of metastatic colorectal cancer: results of the TREE Study J Clin Oncol 26(21) 3523-9 DOI: 10.1200/JCO.2007.15.4138 PMID: 18640933
104. Odom D et al (2011) Health-related quality of life and colorectal cancer-specific symptoms in patients with chemotherapyrefractory metastatic disease treated with panitumumab Int J Colorectal Dis 26(2) 173-81 DOI: 10.1007/s00384-010-1112-5 PMCID: 3024508
105. Ocvirk J et al (2010) Cetuximab plus FOLFOX6 or FOLFIRI in metastatic colorectal cancer: CECOG trial World J Gastroenterol 16(25) 3133-43 DOI: 10.3748/wjg.v16.i25.3133 PMID: 20593498 PMCID: 2896750
106. Van Cutsem E et al (2007) Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer J Clin Oncol 25(13) 1658-64 DOI: 10.1200/JCO.2006.08.1620 PMID: 17470858
107. Peeters M et al (2009) Association of progression-free survival, overall survival, and patient-reported outcomes by skin toxicity and KRAS status in patients receiving panitumumab monotherapy Cancer 115(7) 1544-54 DOI: 10.1002/cncr.24088 PMID: 19189371
108. Degirmenci M et al (2010) Efficacy and safety of bevacizumab plus capecitabine and irinotecan regimen for metastatic colorectal cancer Med Oncol 27(3) 585-91 DOI: 10.1007/s12032-009-9253-5
109. Jubb AM et al (2006) Impact of vascular endothelial growth factor-A expression, thrombospondin-2 expression, and microvessel density on the treatment effect of bevacizumab in metastatic colorectal cancer J Clin Oncol 24(2) 217-27 DOI: 10.1200/JCO.2005.01.5388
110. Lin L et al (2010) Evaluation of bevacizumab combined with irinotecan-based regimen as the first-line treatment for patients with metastatic colorectal cancer Zhonghua Zhong Liu Za Zhi 32(10) 786-90 PMID: 21163073
111. Taieb J, Puig PL and Bedenne L (2008) Cetuximab plus FOLFOX-4 for fully resected stage III colon carcinoma: scientific background and the ongoing PETACC-8 trial Expert Rev Anticancer Ther 8(2) 183-9 DOI: 10.1586/14737140.8.2.183 PMID: 18279058
112. Bokemeyer C et al (2012) Addition of cetuximab to chemotherapy as first-line treatment for KRAS wild-type metastatic colorectal cancer: pooled analysis of the CRYSTAL and OPUS randomised clinical trials Eur J Cancer 48(10) 1466-75 DOI: 10.1016/j.ejca.2012.02.057 PMID: 22446022
113. Ribero D et al (2007) Bevacizumab improves pathologic response and protects against hepatic injury in patients treated with oxaliplatin-based chemotherapy for colorectal liver metastases Cancer 110(12) 2761-7 DOI: 10.1002/cncr.23099 PMID: 17960603
114. Bennett L et al (2011) Health-related quality of life in patients with metastatic colorectal cancer treated with panitumumab in first-or second-line treatment Br J Cancer 105(10) 1495-502 DOI: 10.1038/bjc.2011.409 PMID: 21989186 PMCID: 3242525
115. Bokemeyer C et al (2007) Cetuximab plus 5-FU/FA/oxaliplatin (FOLFOX-4) versus FOLFOX-4 in the first-line treatment of metastatic colorectal cancer (mCRC): OPUS, a randomized phase II study J Clin Oncol 25 4035
116. Moehler M et al (2009) Capecitabine and irinotecan with and without bevacizumab for advanced colorectal cancer patients World J Gastroenterol 15(4) 449-56 DOI: 10.3748/wjg.15.449 PMID: 19152449 PMCID: 2653366
117. Alberts SR et al (2012) Effect of oxaliplatin, fluorouracil, and leucovorin with or without cetuximab on survival among patients with resected stage III colon cancer: a randomized trial JAMA 307(13) 1383-93 DOI: 10.1001/jama.2012.385 PMID: 22474202 PMCID: 3442260
118. Madajewicz S et al (2012) Multicenter, randomized phase II trial of bevacizumab plus folinic acid, fluorouracil, gemcitabine (FFG) versus bevacizumab plus folinic acid, fluorouracil, oxaliplatin (FOLFOX4) as first-line therapy for patients with advanced colorectal cancer Invest New Drugs 30(2) 772-8 DOI: 10.1007/s10637-010-9598-9
119. Snoeren N et al (2010) A randomized two arm phase III study in patients post radical resection of liver metastases of colorectal cancer to investigate bevacizumab in combination with capecitabine plus oxaliplatin (CAPOX) vs CAPOX alone as adjuvant treatment BMC Cancer 10 545 DOI: 10.1186/1471-2407-10-545 PMID: 20937118 PMCID: 2958953
120. Guyatt GH et al (2011) The GRADE Working Group. GRADE guidelines: 9. Rating up the quality of evidence J Clin Epidemiol 64(12) 1311-6 DOI: 10.1016/j.jclinepi.2011.06.004 PMID: 21802902